<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084252</url>
  </required_header>
  <id_info>
    <org_study_id>TED10893</org_study_id>
    <secondary_id>U1111-1116-5472</secondary_id>
    <nct_id>NCT01084252</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies</brief_title>
  <official_title>A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      Phase 1:

      To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984
      (Isatuximab).

      Phase 2 (stage 1):

      To evaluate the activity of single-agent Isatuximab at different doses/schedules and to
      select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as
      single agent or in combination with dexamethasone.

      Phase 2 (stage 2):

      To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the
      selected dose/schedule from stage1, as single agent (ISA arm) and in combination with
      dexamethasone (ISAdex arm).

      Secondary Objectives:

      Phase 1:

        -  To characterize the global safety profile including cumulative toxicities.

        -  To evaluate the pharmacokinetic (PK) profile of Isatuximab in the proposed dosing
           schedule(s).

        -  To assess the pharmacodynamics (PD), immune response, and preliminary disease response.

      Phase 2 (stage 1): to evaluate the following objectives for Isatuximab as single agent:

        -  Safety

        -  Efficacy as measured by duration of response, clinical benefit rate, progression free
           survival, overall survival.

      Phase 2 (stage 2): to evaluate the following objectives in each arm (ISA and ISAdex):

        -  Safety

        -  Efficacy as measured by duration of response, clinical benefit rate, progression free
           survival, overall survival.

        -  Participant-reported changes in health-related quality of life, symptoms of multiple
           myeloma and generic health status.

        -  Pharmacokinetic profile of Isatuximab.

        -  Immunogenicity of Isatuximab.

        -  Investigate the relationship between CD38 receptor density and CD38 receptor occupancy
           (Stage 1 only) on multiple myeloma cells and parameters of clinical response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 1 study duration for an individual participant included a screening period for
      inclusion of up to 2 weeks, treatment with Isatuximab QW (every week) or Q2W (every 2 weeks)
      unless discontinued earlier due to safety or disease progression. Participants were followed
      for a minimum of 30 days following the last use of study drug or more than 30 days in case of
      unresolved toxicity, or up to initiation of another anticancer treatment.

      The Phase 2 study duration for an individual participant included a screening period for
      inclusion of up to 3 weeks, then a treatment period and a follow up period. Treatment was
      continued until disease progression, unacceptable adverse reactions or other reasons for
      discontinuation. Participants were followed every 3 months following the last use of study
      drug until death or study cutoff, whichever came first.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 10, 2010</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Day 1 of Cycle 1 up to Day 14 of Cycle 2</time_frame>
    <description>DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 120 weeks )</time_frame>
    <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria</measure>
    <time_frame>From the date of randomization until disease progression or death or data cut-off (maximum duration: 77 weeks )</time_frame>
    <description>OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and &lt;=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; PR: &gt;=50% reduction of serum M-Protein and reduction in urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours; &gt;=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a &gt;=50% reduction in plasma cells in place of M-protein if present at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria</measure>
    <time_frame>From the date of randomization to date of death from any cause (maximum duration: 97 weeks)</time_frame>
    <description>OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours, &gt;90% decrease in the difference between involved and uninvolved FLC levels; PR: &gt;=50% reduction of serum M-Protein and reduction in urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours; &gt;=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or &gt;=50% reduction in plasma cells in place of M-protein if present at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Assessment: Phase 1: Plasma Concentration of Isatuximab Observed at the End of an Intravenous Infusion (Ceoi)</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 3 Day 1: At the end of infusion</time_frame>
    <description>Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Assessment: Phase 1: Maximum Observed Plasma Concentration (Cmax) of Isatuximab</measure>
    <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion</time_frame>
    <description>Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Assessment: Phase 1: Time to Reach Maximum Plasma Concentration Observed (Tmax) of Isatuximab</measure>
    <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion</time_frame>
    <description>Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Assessment: Phase 1: Plasma Concentration of Isatuximab at Week 1, 2 and 3</measure>
    <time_frame>Week 1, 2 and 3</time_frame>
    <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)</measure>
    <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion</time_frame>
    <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)</measure>
    <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 336 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 336 hr post-infusion</time_frame>
    <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Assessment: Phase 1: Change From Baseline in Serum/Plasma Markers</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessment: Phase 1: Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response</measure>
    <time_frame>Up to 120 weeks</time_frame>
    <description>ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Assessment: Phase 1: Percentage of Participants With Overall Response and Clinical Benefit: Assessed Using European Society for Blood and Marrow Transplantation (EBMT) Criteria</measure>
    <time_frame>From the date of randomization to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)</time_frame>
    <description>OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, &lt;5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: &gt;=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Assessment: Phase 1: Duration of Response (DOR)</measure>
    <time_frame>From the date of first response to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)</time_frame>
    <description>DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: &gt;25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of &gt;= 5 g/l: confirmed by &gt;=1 repeated investigation; &gt;25% increase in 24h urinary light chain excretion, which must also be an absolute increase of &gt;=200 mg/24 h:confirmed by &gt;=1 repeated investigation; &gt;25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of &gt;= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium &gt;11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: &gt;=50% reduction of serum M-protein, reduction in 24h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Assessment: Phase 1: Time to First Response (TTR)</measure>
    <time_frame>From the date of first dose administration to the date of first response or death (due to any cause) (maximum duration: 120 weeks)</time_frame>
    <description>TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: &gt;=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (Karnofsky Performance Status)-Shift From Baseline Value to Best Value During Treatment</measure>
    <time_frame>At baseline, during treatment (Day 1 up to 120 weeks)</time_frame>
    <description>ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest &lt;50% of waking hours; 3=Bed rest/sitting &gt;50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group Performance Status (Karnofsky Performance Status)-Shift From Baseline Value to Worst Value During Treatment</measure>
    <time_frame>At baseline, during treatment (up to 120 weeks)</time_frame>
    <description>ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest &lt;50% of waking hours; 3=Bed rest/sitting&gt;50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 97 weeks)</time_frame>
    <description>AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Duration of Response</measure>
    <time_frame>From the date of first response until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>DOR:Time from date of 1st IAC determined response (&gt;= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:&gt;=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a &gt;=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a &gt;=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein &gt;=0.5 g/dL absolute increase and/or urine M-protein &gt;=200 mg/24 hours absolute increase and/or &gt;10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, &gt;=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium &gt;11·5 mg/dl) attributed to PC proliferation disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 2: Duration of Response</measure>
    <time_frame>From the date of first response until disease progression or death or data cut-off (maximum duration: 97 weeks)</time_frame>
    <description>DOR: Time from date of 1st IAC determined response (&gt;= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of &gt;25% from lowest response value in any one of following: Serum M-component (absolute increase must be &gt;0.5 g/dL)4 and/or Urine M-component (absolute increase must be &gt;200 mg/24 h) and/or &gt;10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, &gt;=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) attributed solely to plasma cell proliferative disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Percentage of Participants With Clinical Benefit</measure>
    <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum &amp; urine, disappearance of any soft tissue plasmacytomas,&lt;5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum &amp; urine M-component detectable by immunofixation, not on electrophoresis/,&gt;=90% reduction in serum M-component plus urine M-component level &lt;100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:&gt;=25 but &lt;49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 2: Percentage of Participants With Clinical Benefit</measure>
    <time_frame>From the date of randomization to the date of first documentation of progression or death (maximum duration: 97 weeks )</time_frame>
    <description>Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum &amp; urine, disappearance of any soft tissue plasmacytomas,&lt;5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum &amp; urine M-component detectable by immunofixation, not on electrophoresis/,&gt;=90% reduction in serum M-component plus urine M-component level &lt;100mg/24h/,&gt;=90% decrease in difference between involved and uninvolved FLC levels; PR:&gt;=50% reduction of serum M-protein, reduction in 24h urinary M-protein by &gt;=90%/&lt;200mg/24h,&gt;50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, &gt;=50% reduction in size/number of soft tissue plasmacytomas. MR:&gt;=25 but &lt;49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Progression Free Survival (PFS)</measure>
    <time_frame>From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of &gt; 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL), Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h), &gt; 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, &gt;10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 2: Progression Free Survival</measure>
    <time_frame>From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 97 weeks)</time_frame>
    <description>PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of &gt;25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be &gt;0.5 g/dL)4 and/or Urine M-component (the absolute increase must be &gt;200 mg/24 h) and/or &gt;10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Overall Survival (OS)</measure>
    <time_frame>From the date of randomization to date of death from any cause (maximum duration 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 2: Overall Survival</measure>
    <time_frame>From the date of randomization to date of death from any cause (maximum duration: 97 weeks)</time_frame>
    <description>OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores: Global Health Status</measure>
    <time_frame>Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and End of Treatment (EOT: anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) &amp; other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health &amp; quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 &amp; 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20) Scores: Disease Symptom Subscale Score</measure>
    <time_frame>Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Stage 1: Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D) Generic Health Status - Visual Analogue Scale Scores</measure>
    <time_frame>Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
    <description>EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval</measure>
    <time_frame>Pre-dose, at the end of infusion, 1 hour and 168 hours post dose on Day 1 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval</measure>
    <time_frame>Cycle 1, Day 1: pre-dose, at the end of infusion, 168 and 336 hours post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval</measure>
    <time_frame>Cycle 1, Day 1: pre-dose, at the end of infusion, 168, 336, and 672 hours post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Phase 2 Stage 2: Plasma Concentration of Isatuximab Before Treatment Administration (Ctrough)</measure>
    <time_frame>At Day 1, 8, and 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Phase 2 Stage 2: Accumulation Ratio of Isatuximab Based on Ctrough</measure>
    <time_frame>Cycle 2, Day 1; Cycle 1, Day 8; Cycle 4, Day 1</time_frame>
    <description>Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessment: Phase 2 Stage 2: Number of Participants With Anti-drug Antibodies to Isatuximab</measure>
    <time_frame>Up to 97 weeks</time_frame>
    <description>ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Hematological Malignancy</condition>
  <arm_group>
    <arm_group_label>Phase 1:Isatuximab &lt;=1 mg/kg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (&lt;=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Isatuximab 3mg/kg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Isatuximab 5 mg/kg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Isatuximab 10 mg/kg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Isatuximab 20 mg/kg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1: Isatuximab 20 mg/kg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Stage 2: Isatuximab Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision maximum exposure: 97 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Stage 2: Isatuximab + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than [&lt;] 75 years of age; 20 mg/day [greater than or equal to [&gt;=] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 97 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab SAR650984</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Phase 1: Isatuximab 10 mg/kg QW</arm_group_label>
    <arm_group_label>Phase 1: Isatuximab 20 mg/kg Q2W</arm_group_label>
    <arm_group_label>Phase 1: Isatuximab 20 mg/kg QW</arm_group_label>
    <arm_group_label>Phase 1: Isatuximab 3mg/kg Q2W</arm_group_label>
    <arm_group_label>Phase 1: Isatuximab 5 mg/kg Q2W</arm_group_label>
    <arm_group_label>Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</arm_group_label>
    <arm_group_label>Phase 1:Isatuximab &lt;=1 mg/kg Q2W</arm_group_label>
    <arm_group_label>Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W</arm_group_label>
    <arm_group_label>Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W</arm_group_label>
    <arm_group_label>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</arm_group_label>
    <arm_group_label>Phase 2 Stage 2: Isatuximab + Dexamethasone</arm_group_label>
    <arm_group_label>Phase 2 Stage 2: Isatuximab Alone</arm_group_label>
    <arm_group_label>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</arm_group_label>
    <arm_group_label>Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W</arm_group_label>
    <other_name>Sarclisa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Phase 2 Stage 2: Isatuximab + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Phase 2 Stage 2: Isatuximab + Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Phase 1:

          -  For dose escalation cohorts, participants with confirmed selected CD38+ hematological
             malignancies as specified below who had progressed on after standard therapy or for
             whom there was no effective standard therapy (refractory/relapsed participants).
             B-cell Non-Hodgkin-lymphoma/leukemia (NHL) participants with at least 1 measurable
             lesion. Multiple myeloma (MM) participants with measurable M-protein serum and/or
             24-hour urine. Acute myeloid leukemia (AML) participants, all types except M3 based on
             French-American-British (FAB) classification. Acute Lymphoblastic Leukemia (B-cell
             ALL) participants. Chronic lymphocytic leukemia (CLL) participants.

          -  For expansion cohorts, participants with relapsed/refractory MM with measurable
             M-protein (serum M-protein of &gt;0.5 g/dL and/or urine M-protein of &gt;200 mg (24-hr
             urine)) or elevated serum free light chains (FLC) &gt;10 mg/dL with abnormal FLC ratio)
             who had progressed on or after standard therapy that included an Immunomodulatory drug
             (IMiD) and a proteasome inhibitor and who met the protocol defined criteria for
             standard risk or high risk.

        Phase 2:

          -  Participants had a known diagnosis of multiple myeloma with evidence of measurable
             disease, and have evidence of disease progression based on International Myeloma
             Working Group (IMWG) criteria: Serum M-protein ≥1 g/dL, or urine M-protein &gt;=200 mg/24
             hours or in the absence of measurable m-protein, serum FLC &gt;=10 mg/dL, and abnormal
             serum immunoglobulin kappa lambda FLC ratio (&lt;0.26 or &gt;1.65).

          -  Participants who received at least three prior lines of therapy for MM and had
             treatment with an IMiD (for &gt;=2 cycles or &gt;=2 months of treatment) and a proteasome
             inhibitor (PI) (for &gt;=2 cycles or &gt;=2 months of treatment) OR participants whose
             disease was double refractory to an IMiD and a PI. For participants who had received
             more than 1 type of IMiD and PI, their disease must be refractory to the most recent
             one.

          -  Participants who had achieved a minimal response or better to at least one prior line
             of therapy.

          -  Participants who had received an alkylating agent (&gt;=2 cycles or &gt;=2 months) either
             alone or in combination with other MM treatments.

          -  Stage 2 only: Participants who had evidence of disease progression on or after the
             most recent prior regimen based on IMWG criteria.

        Exclusion criteria:

        Phase 1:

          -  Karnofsky performance status &lt;60

          -  Poor bone marrow reserve

          -  Poor organ function

          -  Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or
             known hypersensitivity to any of the components of the study therapy that was not
             amenable to pre-medication with steroids and H2 blockers

          -  Any serious active disease (including clinically significant infection that was
             chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the
             investigator, interfered with the safety, the compliance with the study or with the
             interpretation of the results

          -  Any severe underlying medical conditions including presence of laboratory
             abnormalities, which could impair the ability to participate in the study or the
             interpretation of its results

        Phase 2:

          -  Participants with multiple myeloma immunoglobulin M (IgM) subtype

          -  Previous treatment with any anti-CD38 therapy

          -  Participants with concurrent plasma cell leukemia

          -  Participants with known or suspected amyloidosis

          -  Karnofsky performance status &lt;60 (stage 1)/Eastern Cooperative Oncology Group (ECOG)
             Performance status &gt;2 (stage 2).

          -  Poor bone marrow reserve

          -  Poor organ function

          -  Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or
             known hypersensitivity to any of the components of the study therapy that was not
             amenable to pre-medication with steroids and H2 blockers

          -  Any serious active disease (including clinically significant infection that was
             chronic, recurrent, or active) or co-morbid condition, which, in the opinion of the
             investigator, interfered with the safety, the compliance with the study or with the
             interpretation of the results

          -  Any severe underlying medical conditions including presence of laboratory
             abnormalities, which impaired the ability to participate in the study or the
             interpretation of its results

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840022</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840027</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840018</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840013</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840014</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840016</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840012</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840017</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032002</name>
      <address>
        <city>Caba</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032003</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1425ASS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 032001</name>
      <address>
        <city>Ciudad De Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076001</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076003</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076004</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076002</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04537-081</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 152001</name>
      <address>
        <city>Temuco</city>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246001</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246002</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300001</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376004</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376002</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484001</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484003</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78419</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 604001</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 604002</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643002</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643003</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643001</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643004</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724007</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724005</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724008</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724006</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792002</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792005</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792001</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792004</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804001</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804004</name>
      <address>
        <city>Vinnitsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804002</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826001</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826002</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>March 31, 2020</results_first_submitted>
  <results_first_submitted_qc>March 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 15, 2020</results_first_posted>
  <disposition_first_submitted>December 7, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 7, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 10, 2019</disposition_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-CD38 monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to participant level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Participant level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT01084252/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT01084252/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were involved in the study from 10 June 2010 at 59 centers in 18 countries. A total of 418 participants were screened, of which 351 participants were enrolled. A total of 67 participants had screen failures due to failure to meet inclusion criteria.</recruitment_details>
      <pre_assignment_details>Study consisted 2 phases: Phase 1 and Phase 2. Phase 1 was a dose escalation part of isatuximab to determine maximum tolerated dose (MTD). Phase 2 was conducted for efficacy and safety evaluation of isatuximab with or without dexamethasone. It was consisted of 2 stages: Stage 1 (comprised of 1a and 1b) and Stage 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase1: Isatuximab &lt;=1 mg/kg Every 2 Weeks (Q2W)</title>
          <description>Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (&lt;=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg, or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P2">
          <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P3">
          <title>Phase 1: Isatuximab 5 mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P4">
          <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
          <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P5">
          <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
          <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P6">
          <title>Phase 1: Isatuximab 10 mg/kg Every Week (QW)</title>
          <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P7">
          <title>Phase 1: Isatuximab 20 mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P8">
          <title>Phase 1: Isatuximab 20 mg/kg QW</title>
          <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="P9">
          <title>Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="P10">
          <title>Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="P11">
          <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
          <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 weeks (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="P12">
          <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
        </group>
        <group group_id="P13">
          <title>Phase 2 Stage 2: Isatuximab Alone</title>
          <description>Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
        </group>
        <group group_id="P14">
          <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
          <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than [&lt;] 75 years of age; 20 mg/day for greater than or equal to [&gt;=] 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1 (120 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Treated (AT) Population</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="23">Phase 1, Phase 2 Stage 1 and Phase 2 Stage 2 were separate populations.</participants>
                <participants group_id="P10" count="24">Phase 1, Phase 2 Stage 1 and Phase 2 Stage 2 were separate populations.</participants>
                <participants group_id="P11" count="25">Phase 1, Phase 2 Stage 1 and Phase 2 Stage 2 were separate populations.</participants>
                <participants group_id="P12" count="25">Phase 1, Phase 2 Stage 1 and Phase 2 Stage 2 were separate populations.</participants>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>AT Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="23"/>
                <participants group_id="P10" count="24"/>
                <participants group_id="P11" count="25"/>
                <participants group_id="P12" count="25"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="23"/>
                <participants group_id="P10" count="24"/>
                <participants group_id="P11" count="25"/>
                <participants group_id="P12" count="25"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="17"/>
                <participants group_id="P12" count="19"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2 Stage 2 (97 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="110">Phase 1, Phase 2 Stage 1 and Phase 2 Stage 2 were separate populations.</participants>
                <participants group_id="P14" count="55">Phase 1, Phase 2 Stage 1 and Phase 2 Stage 2 were separate populations.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>AT Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="109"/>
                <participants group_id="P14" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="110"/>
                <participants group_id="P14" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="13"/>
                <participants group_id="P14" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="70"/>
                <participants group_id="P14" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="13"/>
                <participants group_id="P14" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolled, but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on AT population.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1:Isatuximab &lt;=1 mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab at any one of the dose &lt;= 1 mg/kg (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg, or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B2">
          <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B3">
          <title>Phase 1: Isatuximab 5 mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B4">
          <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
          <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B5">
          <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
          <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B6">
          <title>Phase 1: Isatuximab 10 mg/kg QW</title>
          <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B7">
          <title>Phase 1: Isatuximab 20 mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B8">
          <title>Phase 1: Isatuximab 20 mg/kg QW</title>
          <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="B9">
          <title>Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="B10">
          <title>Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="B11">
          <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
          <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="B12">
          <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1,8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
        </group>
        <group group_id="B13">
          <title>Phase 2 Stage 2: Isatuximab Alone</title>
          <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
        </group>
        <group group_id="B14">
          <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
          <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="18"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="23"/>
            <count group_id="B10" value="24"/>
            <count group_id="B11" value="25"/>
            <count group_id="B12" value="25"/>
            <count group_id="B13" value="109"/>
            <count group_id="B14" value="55"/>
            <count group_id="B15" value="350"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="11.6"/>
                    <measurement group_id="B2" value="63.5" spread="6.2"/>
                    <measurement group_id="B3" value="62.0" spread="3.5"/>
                    <measurement group_id="B4" value="65.0" spread="7.2"/>
                    <measurement group_id="B5" value="60.8" spread="12.6"/>
                    <measurement group_id="B6" value="61.7" spread="12.7"/>
                    <measurement group_id="B7" value="63.3" spread="10.0"/>
                    <measurement group_id="B8" value="60.0" spread="8.3"/>
                    <measurement group_id="B9" value="63.2" spread="8.9"/>
                    <measurement group_id="B10" value="63.9" spread="8.8"/>
                    <measurement group_id="B11" value="61.0" spread="7.3"/>
                    <measurement group_id="B12" value="61.1" spread="10.3"/>
                    <measurement group_id="B13" value="66.6" spread="8.8"/>
                    <measurement group_id="B14" value="66.3" spread="8.9"/>
                    <measurement group_id="B15" value="64.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="11"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="13"/>
                    <measurement group_id="B13" value="58"/>
                    <measurement group_id="B14" value="26"/>
                    <measurement group_id="B15" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="18"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="51"/>
                    <measurement group_id="B14" value="29"/>
                    <measurement group_id="B15" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="21"/>
                    <measurement group_id="B10" value="19"/>
                    <measurement group_id="B11" value="19"/>
                    <measurement group_id="B12" value="21"/>
                    <measurement group_id="B13" value="91"/>
                    <measurement group_id="B14" value="45"/>
                    <measurement group_id="B15" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="11"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)</title>
        <description>DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT.</description>
        <time_frame>Day 1 of Cycle 1 up to Day 14 of Cycle 2</time_frame>
        <population>DLT evaluable population included participants who gave their informed consent, received at least 1 dose of isatuximab during Phase 1 and had a DLT assessment at the end of Cycle 2. Data was planned not to be collected and analyzed for the arm: Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma).</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1:Isatuximab &lt;=1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab at any one of the dose &lt;= 1 mg/kg (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg, or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab 10 mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)</title>
          <description>DLTs were assessed using the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03. DLTs were defined as any Grade 3 or higher non-hematological toxicity (with the exception of allergic reaction/hypersensitivity), Grade 4 neutropenia and/or Grade 4 thrombocytopenia lasting longer than 5 days, attributed to isatuximab. Any other toxicity that the Investigator and the Sponsor deemed to be dose-limiting, regardless of the grade, was also considered as DLT.</description>
          <population>DLT evaluable population included participants who gave their informed consent, received at least 1 dose of isatuximab during Phase 1 and had a DLT assessment at the end of Cycle 2. Data was planned not to be collected and analyzed for the arm: Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
        <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 120 weeks )</time_frame>
        <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab &lt;=1mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab at any one of the dose &lt;= 1 mg/kg (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg, or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 10 mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks)..</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
          <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria</title>
        <description>OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and &lt;=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; PR: &gt;=50% reduction of serum M-Protein and reduction in urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours; &gt;=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a &gt;=50% reduction in plasma cells in place of M-protein if present at baseline.</description>
        <time_frame>From the date of randomization until disease progression or death or data cut-off (maximum duration: 77 weeks )</time_frame>
        <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3 mg/kg</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10 mg/kg</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W and Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Percentage of Participants With Overall Response (OR) According to International Myeloma Working Group (IMWG) Uniform Response Criteria</title>
          <description>OR defined as participants with stringent complete response (sCR) or complete response (CR) or very good partial response (VGPR) or partial response (PR) . Based on IMWG, CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and &lt;=5% plasma cells in bone marrow; sCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours; PR: &gt;=50% reduction of serum M-Protein and reduction in urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours; &gt;=50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a &gt;=50% reduction in plasma cells in place of M-protein if present at baseline.</description>
          <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria</title>
        <description>OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours, &gt;90% decrease in the difference between involved and uninvolved FLC levels; PR: &gt;=50% reduction of serum M-Protein and reduction in urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours; &gt;=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or &gt;=50% reduction in plasma cells in place of M-protein if present at baseline.</description>
        <time_frame>From the date of randomization to date of death from any cause (maximum duration: 97 weeks)</time_frame>
        <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 2: Percentage of Participants With Overall Response According to Updated IMWG Response Criteria</title>
          <description>OR: participants with sCR or CR or VGPR or PR. As per updated IMWG, CR: Negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and &lt;=5% plasma cells in bone marrow; normal FLC ratio of 0.26-1.65 in participants with only FLC disease; sCR: CR and normal FLC ratio and no clonal cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt;=90% reduction in serum M-protein and urine M-protein level &lt;100 mg/24 hours, &gt;90% decrease in the difference between involved and uninvolved FLC levels; PR: &gt;=50% reduction of serum M-Protein and reduction in urinary M-protein by &gt;=90% or to &lt;200 mg/24 hours; &gt;=50% decrease in the difference between involved and uninvolved FLC levels in place of M-protein criteria or &gt;=50% reduction in plasma cells in place of M-protein if present at baseline.</description>
          <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Assessment: Phase 1: Plasma Concentration of Isatuximab Observed at the End of an Intravenous Infusion (Ceoi)</title>
        <description>Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.</description>
        <time_frame>Cycle 1 Day 1 and Cycle 3 Day 1: At the end of infusion</time_frame>
        <population>Here, &quot;Overall Number of Participants Analyzed&quot;=participants evaluable for this outcome measure and “0” in “number analyzed” field signifies none of the participant were evaluable because at Cycle 3, Day 1, only data for reporting arms “Phase 1: Isatuximab 10mg/kg QW” and “Phase 1: Isatuximab 20mg/kg QW” was planned to be collected and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 0.3 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 0.3 mg/kg, as IV infusion on Day 1of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unaccepted toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O9">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Assessment: Phase 1: Plasma Concentration of Isatuximab Observed at the End of an Intravenous Infusion (Ceoi)</title>
          <description>Ceoi was defined as the plasma concentration of Isatuximab at end of infusion. Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population: participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.</description>
          <population>Here, &quot;Overall Number of Participants Analyzed&quot;=participants evaluable for this outcome measure and “0” in “number analyzed” field signifies none of the participant were evaluable because at Cycle 3, Day 1, only data for reporting arms “Phase 1: Isatuximab 10mg/kg QW” and “Phase 1: Isatuximab 20mg/kg QW” was planned to be collected and analyzed.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08667" spread="0.65567"/>
                    <measurement group_id="O2" value="13.18333" spread="5.74464"/>
                    <measurement group_id="O3" value="44.22500" spread="15.30651"/>
                    <measurement group_id="O4" value="125.50000" spread="53.03301"/>
                    <measurement group_id="O5" value="171.43333" spread="50.18853"/>
                    <measurement group_id="O6" value="148.80000" spread="18.48513"/>
                    <measurement group_id="O7" value="400.33333" spread="52.51984"/>
                    <measurement group_id="O8" value="173.33333" spread="20.64784"/>
                    <measurement group_id="O9" value="334.33333" spread="98.28462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="299.82500" spread="220.83898"/>
                    <measurement group_id="O9" value="715.33333" spread="188.01241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Assessment: Phase 1: Maximum Observed Plasma Concentration (Cmax) of Isatuximab</title>
        <description>Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population.</description>
        <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion</time_frame>
        <population>Here, &quot;Overall Number of Participants Analyzed&quot;=participants evaluable for this outcome measure and “0” in “number analyzed” field signifies none of the participant were evaluable because at Cycle 3, Day 1, only data for reporting arms “Phase 1: Isatuximab 10mg/kg QW” and “Phase 1: Isatuximab 20mg/kg QW” was planned to be collected and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 0.3 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 0.3 mg/kg, as IV infusion on Day 1of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unaccepted toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O9">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Assessment: Phase 1: Maximum Observed Plasma Concentration (Cmax) of Isatuximab</title>
          <description>Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population.</description>
          <population>Here, &quot;Overall Number of Participants Analyzed&quot;=participants evaluable for this outcome measure and “0” in “number analyzed” field signifies none of the participant were evaluable because at Cycle 3, Day 1, only data for reporting arms “Phase 1: Isatuximab 10mg/kg QW” and “Phase 1: Isatuximab 20mg/kg QW” was planned to be collected and analyzed.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="31"/>
                    <measurement group_id="O2" value="12.4" spread="45"/>
                    <measurement group_id="O3" value="53.7" spread="28"/>
                    <measurement group_id="O4" value="126" spread="NA">Geometric Coefficient of Variation was not calculated because it was pre-specified not to calculate the value if number of participants was &lt;=2.</measurement>
                    <measurement group_id="O5" value="181" spread="48"/>
                    <measurement group_id="O6" value="154" spread="13"/>
                    <measurement group_id="O7" value="457" spread="28"/>
                    <measurement group_id="O8" value="181" spread="20"/>
                    <measurement group_id="O9" value="343" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="265" spread="67"/>
                    <measurement group_id="O9" value="712" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Assessment: Phase 1: Time to Reach Maximum Plasma Concentration Observed (Tmax) of Isatuximab</title>
        <description>Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population.</description>
        <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion</time_frame>
        <population>Here, &quot;Overall Number of Participants Analyzed&quot;=participants evaluable for this outcome measure and “0” in “number analyzed” field signifies none of the participant were evaluable because at Cycle 3, Day 1, only data for reporting arms “Phase 1: Isatuximab 10mg/kg QW” and “Phase 1: Isatuximab 20mg/kg QW” was planned to be collected and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 0.3 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 0.3 mg/kg, as IV infusion on Day 1of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unaccepted toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O9">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Assessment: Phase 1: Time to Reach Maximum Plasma Concentration Observed (Tmax) of Isatuximab</title>
          <description>Data for this outcome measure was planned to be collected and analyzed separately for dose 0.3 mg/kg, 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03 and 0.1 dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow). Analysis was performed on PK population.</description>
          <population>Here, &quot;Overall Number of Participants Analyzed&quot;=participants evaluable for this outcome measure and “0” in “number analyzed” field signifies none of the participant were evaluable because at Cycle 3, Day 1, only data for reporting arms “Phase 1: Isatuximab 10mg/kg QW” and “Phase 1: Isatuximab 20mg/kg QW” was planned to be collected and analyzed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" lower_limit="1.42" upper_limit="3.43"/>
                    <measurement group_id="O2" value="4.35" lower_limit="3.13" upper_limit="6.33"/>
                    <measurement group_id="O3" value="6.99" lower_limit="4.58" upper_limit="8.00"/>
                    <measurement group_id="O4" value="7.65" lower_limit="5.13" upper_limit="10.17"/>
                    <measurement group_id="O5" value="4.28" lower_limit="2.15" upper_limit="9.37"/>
                    <measurement group_id="O6" value="4.92" lower_limit="2.60" upper_limit="30.08"/>
                    <measurement group_id="O7" value="5.87" lower_limit="5.78" upper_limit="9.90"/>
                    <measurement group_id="O8" value="2.25" lower_limit="2.20" upper_limit="7.50"/>
                    <measurement group_id="O9" value="6.83" lower_limit="3.98" upper_limit="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="4.30" lower_limit="2.57" upper_limit="27.48"/>
                    <measurement group_id="O9" value="8.07" lower_limit="2.87" upper_limit="29.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Assessment: Phase 1: Plasma Concentration of Isatuximab at Week 1, 2 and 3</title>
        <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
        <time_frame>Week 1, 2 and 3</time_frame>
        <population>Analysis was performed on PK population. Here, ‘number analyzed’ = number of participants with available data for each category.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 10 mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Assessment: Phase 1: Plasma Concentration of Isatuximab at Week 1, 2 and 3</title>
          <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
          <population>Analysis was performed on PK population. Here, ‘number analyzed’ = number of participants with available data for each category.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00223" spread="86"/>
                    <measurement group_id="O2" value="1.44" spread="85"/>
                    <measurement group_id="O3" value="15.3" spread="90"/>
                    <measurement group_id="O4" value="27.6" spread="81"/>
                    <measurement group_id="O5" value="44.2" spread="52"/>
                    <measurement group_id="O6" value="20.7" spread="63"/>
                    <measurement group_id="O7" value="113" spread="37"/>
                    <measurement group_id="O8" value="108" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000800" spread="173"/>
                    <measurement group_id="O2" value="0.181" spread="136"/>
                    <measurement group_id="O3" value="1.39" spread="116"/>
                    <measurement group_id="O4" value="1.97" spread="145"/>
                    <measurement group_id="O5" value="8.31" spread="77"/>
                    <measurement group_id="O6" value="55.1" spread="63"/>
                    <measurement group_id="O7" value="63.9" spread="46"/>
                    <measurement group_id="O8" value="194.8" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000283" spread="145"/>
                    <measurement group_id="O2" value="0.460" spread="121"/>
                    <measurement group_id="O3" value="42.7" spread="73"/>
                    <measurement group_id="O4" value="4.18" spread="133"/>
                    <measurement group_id="O5" value="18.6" spread="71"/>
                    <measurement group_id="O6" value="75.9" spread="78"/>
                    <measurement group_id="O7" value="91.0" spread="52"/>
                    <measurement group_id="O8" value="347.3" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)</title>
        <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
        <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 168 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 168 hr post-infusion</time_frame>
        <population>Analysis was performed on PK population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unaccepted toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks)</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First Week (0-168 Hours) (AUC1W)</title>
          <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
          <population>Analysis was performed on PK population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>mcg*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222" spread="80"/>
                    <measurement group_id="O2" value="2624" spread="24"/>
                    <measurement group_id="O3" value="7174" spread="54"/>
                    <measurement group_id="O4" value="11566" spread="48"/>
                    <measurement group_id="O5" value="13480" spread="38"/>
                    <measurement group_id="O6" value="12680" spread="35"/>
                    <measurement group_id="O7" value="32739" spread="28"/>
                    <measurement group_id="O8" value="28405" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)</title>
        <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
        <time_frame>For Q2W:Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 3, 7, 24, 48 and 336 hr post-infusion; For QW: Cycle 1,Day 1: pre-dose, 15 min after start of infusion, at the end of infusion, 4, 24, 48, 72 and 336 hr post-infusion</time_frame>
        <population>Analysis was performed on PK population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unaccepted toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>PK Assessment: Phase 1: Predicted Cumulative Area Under the Plasma Concentration Curve (AUC) of Isatuximab Over the First 2 Weeks (0-336 Hours) (AUC2W)</title>
          <description>Data for this outcome measure was planned to be collected and analyzed only for dose 1 mg/kg and not for 0.0001, 0.001, 0.01, 0.03, 0.1 and 0.3 mg/kg dose levels (reported under one arm, i.e. Phase 1: Isatuximab &lt;=1mg/kg in participant flow).</description>
          <population>Analysis was performed on PK population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure.</population>
          <units>mcg*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222" spread="80"/>
                    <measurement group_id="O2" value="3076" spread="35"/>
                    <measurement group_id="O3" value="9546" spread="70"/>
                    <measurement group_id="O4" value="14876" spread="64"/>
                    <measurement group_id="O5" value="18967" spread="44"/>
                    <measurement group_id="O6" value="30187" spread="40"/>
                    <measurement group_id="O7" value="48003" spread="31"/>
                    <measurement group_id="O8" value="71174" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic (PD) Assessment: Phase 1: Change From Baseline in Serum/Plasma Markers</title>
        <description>Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed.</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>Analysis was performed on all randomized participants who gave their informed consent, had received at least 1 dose (even incomplete) of isatuximab and had an assessable PD parameter. Here, ‘number analyzed’ = number of participants with available data for each category.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1:Isatuximab &lt;=1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab at any one of the dose &lt;= 1 mg/kg (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg, or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma , received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic (PD) Assessment: Phase 1: Change From Baseline in Serum/Plasma Markers</title>
          <description>Serum/plasma markers included: tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1-β), interleukin 6 (IL-6) and interferon-gamma (IFN-Gamma). Due to change in planned analysis, data for high-sensitivity C-reactive protein (hs-CRP) and CD38 was not collected and analyzed.</description>
          <population>Analysis was performed on all randomized participants who gave their informed consent, had received at least 1 dose (even incomplete) of isatuximab and had an assessable PD parameter. Here, ‘number analyzed’ = number of participants with available data for each category.</population>
          <units>picogram/milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF alpha</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.181" spread="253.373"/>
                    <measurement group_id="O2" value="179.783" spread="191.455"/>
                    <measurement group_id="O3" value="352.974" spread="220.394"/>
                    <measurement group_id="O4" value="340.799" spread="341.100"/>
                    <measurement group_id="O5" value="503.462" spread="479.813"/>
                    <measurement group_id="O6" value="342.664" spread="410.245"/>
                    <measurement group_id="O7" value="307.319" spread="398.025"/>
                    <measurement group_id="O8" value="412.541" spread="243.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1 Beta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.577" spread="227.399"/>
                    <measurement group_id="O2" value="29.741" spread="55.515"/>
                    <measurement group_id="O3" value="7.527" spread="8.118"/>
                    <measurement group_id="O4" value="299.058" spread="572.260"/>
                    <measurement group_id="O5" value="547.770" spread="1454.175"/>
                    <measurement group_id="O6" value="327.957" spread="759.305"/>
                    <measurement group_id="O7" value="305.914" spread="621.754"/>
                    <measurement group_id="O8" value="293.307" spread="612.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.234" spread="212.385"/>
                    <measurement group_id="O2" value="261.732" spread="270.119"/>
                    <measurement group_id="O3" value="73.899" spread="53.211"/>
                    <measurement group_id="O4" value="148.594" spread="175.719"/>
                    <measurement group_id="O5" value="173.004" spread="433.297"/>
                    <measurement group_id="O6" value="-8.109" spread="45.845"/>
                    <measurement group_id="O7" value="274.616" spread="234.752"/>
                    <measurement group_id="O8" value="165.295" spread="203.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN Gamma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477.116" spread="1673.063"/>
                    <measurement group_id="O2" value="5.376" spread="9.312"/>
                    <measurement group_id="O3" value="25.806" spread="44.698"/>
                    <measurement group_id="O4" value="445.772" spread="1043.982"/>
                    <measurement group_id="O5" value="568.806" spread="1022.000"/>
                    <measurement group_id="O6" value="627.089" spread="1527.647"/>
                    <measurement group_id="O7" value="448.387" spread="569.499"/>
                    <measurement group_id="O8" value="1487.097" spread="2693.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Assessment: Phase 1: Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response</title>
        <description>ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.</description>
        <time_frame>Up to 120 weeks</time_frame>
        <population>Analysis was performed on ADA evaluable population which included all treated participants with at least one ADA assessment with a reportable result during the ADA on-study observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1:Isatuximab &lt;=1 mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab at any one of the dose &lt;= 1 mg/kg (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg, or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure:
120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unaccepted toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Assessment: Phase 1: Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response</title>
          <description>ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 1) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.</description>
          <population>Analysis was performed on ADA evaluable population which included all treated participants with at least one ADA assessment with a reportable result during the ADA on-study observation period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="26"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-induced ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment boosted ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Assessment: Phase 1: Percentage of Participants With Overall Response and Clinical Benefit: Assessed Using European Society for Blood and Marrow Transplantation (EBMT) Criteria</title>
        <description>OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, &lt;5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: &gt;=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.</description>
        <time_frame>From the date of randomization to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)</time_frame>
        <population>Analysis was performed on all-treated population. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 1mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O8">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Assessment: Phase 1: Percentage of Participants With Overall Response and Clinical Benefit: Assessed Using European Society for Blood and Marrow Transplantation (EBMT) Criteria</title>
          <description>OR defined as participants with complete response (CR) or partial response (PR) as best overall response (BOR). Clinical benefit: participants with minimal response (MR) or better as BOR. BOR: best sequential response from start of treatment through the entire study excluding any time point following start of other treatment. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, &lt;5% plasma cells in bone marrow aspirates, no increase in size or number of lytic bone lesions. PR: &gt;=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions. MR: 25 to 49% reduction in serum M-protein, 50-89% reduction in 24h urine M-protein, 25-49% reduction in size of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.</description>
          <population>Analysis was performed on all-treated population. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="28.0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="14.3"/>
                    <measurement group_id="O8" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical benefit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="28.0"/>
                    <measurement group_id="O5" value="27.8"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="28.6"/>
                    <measurement group_id="O8" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Assessment: Phase 1: Duration of Response (DOR)</title>
        <description>DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: &gt;25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of &gt;= 5 g/l: confirmed by &gt;=1 repeated investigation; &gt;25% increase in 24h urinary light chain excretion, which must also be an absolute increase of &gt;=200 mg/24 h:confirmed by &gt;=1 repeated investigation; &gt;25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of &gt;= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium &gt;11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: &gt;=50% reduction of serum M-protein, reduction in 24h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions.</description>
        <time_frame>From the date of first response to the date of first documentation of progression or death (due to any cause) (maximum duration: 120 weeks)</time_frame>
        <population>Analysis was performed only on subset of participants who had response in Phase 1 and not for the reporting group with no response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 1mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unaccepted toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks)</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Assessment: Phase 1: Duration of Response (DOR)</title>
          <description>DOR: time from first response (PR or better) to first documented tumor progression/death. Progression as per EBMT: &gt;25% increase in serum monoclonal paraprotein level, which must also be an absolute increase of &gt;= 5 g/l: confirmed by &gt;=1 repeated investigation; &gt;25% increase in 24h urinary light chain excretion, which must also be an absolute increase of &gt;=200 mg/24 h:confirmed by &gt;=1 repeated investigation; &gt;25% increase in plasma cells in a bone marrow aspirate/on trephine biopsy, which must also be an absolute increase of &gt;= 10%; definite increase in size of existing bone lesions/soft tissue plasmacytomas; development of new bone lesions/soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium &gt;11·5 mg/dl or 2·8 mmol/l) not attributable to any other cause. PR: &gt;=50% reduction of serum M-protein, reduction in 24h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size/number of lytic bone lesions.</description>
          <population>Analysis was performed only on subset of participants who had response in Phase 1 and not for the reporting group with no response.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.21"/>
                    <measurement group_id="O2" value="7.16"/>
                    <measurement group_id="O3" value="5.76" spread="4.62"/>
                    <measurement group_id="O4" value="10.70" spread="11.25"/>
                    <measurement group_id="O5" value="14.31" spread="7.50"/>
                    <measurement group_id="O6" value="3.94"/>
                    <measurement group_id="O7" value="8.82" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Assessment: Phase 1: Time to First Response (TTR)</title>
        <description>TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: &gt;=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.</description>
        <time_frame>From the date of first dose administration to the date of first response or death (due to any cause) (maximum duration: 120 weeks)</time_frame>
        <population>Analysis was performed only on subset of participants who had response in Phase 1 and not for the reporting group with no response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab 1mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
            <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included in this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: Isatuximab 10mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
          <group group_id="O7">
            <title>Phase 1: Isatuximab 20mg/kg QW</title>
            <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Assessment: Phase 1: Time to First Response (TTR)</title>
          <description>TTR was defined as the time from first dose of isatuximab to first response (PR or better). PR: &gt;=50% reduction of serum M-protein, reduction in 24 h urinary M-protein by &gt;=90% or &lt;200mg, &gt;=50% reduction in size/number of soft tissue plasmacytomas, no increase in size or number of lytic bone lesions.</description>
          <population>Analysis was performed only on subset of participants who had response in Phase 1 and not for the reporting group with no response.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95"/>
                    <measurement group_id="O2" value="6.41"/>
                    <measurement group_id="O3" value="2.52" spread="3.77"/>
                    <measurement group_id="O4" value="1.96" spread="1.72"/>
                    <measurement group_id="O5" value="1.38" spread="0.65"/>
                    <measurement group_id="O6" value="1.18"/>
                    <measurement group_id="O7" value="1.46" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (Karnofsky Performance Status)-Shift From Baseline Value to Best Value During Treatment</title>
        <description>ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest &lt;50% of waking hours; 3=Bed rest/sitting &gt;50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported.</description>
        <time_frame>At baseline, during treatment (Day 1 up to 120 weeks)</time_frame>
        <population>Analysis was performed on AT population. Data for this outcome measure was planned to be collected and analyzed for a combined arm of overall Phase 1 AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab</title>
            <description>All participants who were enrolled in Phase 1 and received Isatuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (Karnofsky Performance Status)-Shift From Baseline Value to Best Value During Treatment</title>
          <description>ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest &lt;50% of waking hours; 3=Bed rest/sitting &gt;50% of waking hours; 4=Bedridden or unable to care for self, where lower score indicated good performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the best values (categorized as: Baseline ECOG 1, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 0; Baseline ECOG 2, During Treatment ECOG 1) are reported.</description>
          <population>Analysis was performed on AT population. Data for this outcome measure was planned to be collected and analyzed for a combined arm of overall Phase 1 AT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ECOG 1, During Treatment ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 2, During Treatment ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 2, During Treatment ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group Performance Status (Karnofsky Performance Status)-Shift From Baseline Value to Worst Value During Treatment</title>
        <description>ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest &lt;50% of waking hours; 3=Bed rest/sitting&gt;50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported.</description>
        <time_frame>At baseline, during treatment (up to 120 weeks)</time_frame>
        <population>Analysis was performed on AT population. Data for this outcome measure was planned to be collected and analyzed for a combined arm of overall Phase 1 AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: Isatuximab</title>
            <description>All participants who were enrolled in Phase 1 and received Isatuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Assessment: Phase 1: Number of Participants With Eastern Cooperative Oncology Group Performance Status (Karnofsky Performance Status)-Shift From Baseline Value to Worst Value During Treatment</title>
          <description>ECOG performance status was measured on a 4 point scale to assess participant's performance status. 0=Normal, fully functional; 1=Fatigue without significant decrease in daily activity; 2=Fatigue with significant impairment of daily activities or bed rest &lt;50% of waking hours; 3=Bed rest/sitting&gt;50% of waking hours; 4=Bedridden or unable to care for self, where higher score indicated worst performance status. Number of participants with Baseline ECOG PS score and corresponding changes to the worst values (categorized as: Baseline ECOG 0, During Treatment ECOG 1; Baseline ECOG 2, During Treatment ECOG 1; Baseline ECOG 0, During Treatment ECOG 2; Baseline ECOG 1, During Treatment ECOG 2; Baseline ECOG 0, During Treatment ECOG 3; Baseline ECOG 1, During Treatment ECOG 3; Baseline ECOG 2, During Treatment ECOG 3) are reported.</description>
          <population>Analysis was performed on AT population. Data for this outcome measure was planned to be collected and analyzed for a combined arm of overall Phase 1 AT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ECOG 0, During Treatment ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 2, During Treatment ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 0, During Treatment ECOG 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 1, During Treatment ECOG 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 0, During Treatment ECOG 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 1, During Treatment ECOG 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ECOG 2, During Treatment ECOG 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
        <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed on AT population which included Participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
          <population>Analysis was performed on AT population which included Participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
        <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 97 weeks)</time_frame>
        <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on-treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment.</description>
          <population>Analysis was performed on AT population which included participants who signed informed consent &amp; received at least 1 dose/even incomplete of isatuximab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Duration of Response</title>
        <description>DOR:Time from date of 1st IAC determined response (&gt;= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:&gt;=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a &gt;=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a &gt;=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein &gt;=0.5 g/dL absolute increase and/or urine M-protein &gt;=200 mg/24 hours absolute increase and/or &gt;10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, &gt;=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium &gt;11·5 mg/dl) attributed to PC proliferation disorder.</description>
        <time_frame>From the date of first response until disease progression or death or data cut-off (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed only on subset of population who had response in Phase 2 stage 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Duration of Response</title>
          <description>DOR:Time from date of 1st IAC determined response (&gt;= PR) that was subsequently confirmed, to date of first IAC determined PD/death, whichever happened earlier. updated IMWG criteria- PR:&gt;=50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or a &gt;=50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a &gt;=50% reduction in size of soft tissue plasmacytomas; PD: Increase of 25% from lowest response value in any of following: Serum M-protein &gt;=0.5 g/dL absolute increase and/or urine M-protein &gt;=200 mg/24 hours absolute increase and/or &gt;10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, &gt;=10% bone marrow plasma cells (PCs), development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium &gt;11·5 mg/dl) attributed to PC proliferation disorder.</description>
          <population>Analysis was performed only on subset of population who had response in Phase 2 stage 1.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91"/>
                    <measurement group_id="O2" value="11.17" spread="5.77"/>
                    <measurement group_id="O3" value="7.31" spread="3.65"/>
                    <measurement group_id="O4" value="8.11" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 2: Duration of Response</title>
        <description>DOR: Time from date of 1st IAC determined response (&gt;= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of &gt;25% from lowest response value in any one of following: Serum M-component (absolute increase must be &gt;0.5 g/dL)4 and/or Urine M-component (absolute increase must be &gt;200 mg/24 h) and/or &gt;10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, &gt;=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) attributed solely to plasma cell proliferative disorder.</description>
        <time_frame>From the date of first response until disease progression or death or data cut-off (maximum duration: 97 weeks)</time_frame>
        <population>Analysis was performed only on subset of population who had response in Phase 2 stage 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 2: Duration of Response</title>
          <description>DOR: Time from date of 1st IAC determined response (&gt;= PR) that was subsequently confirmed, to date of 1st IAC determined PD or death, whichever happened earlier. As per updated IMWG criteria-PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours. ≥50% decrease in difference between involved and uninvolved FLC levels in place of M-protein criteria or ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline ≥50% reduction in size of soft tissue plasmacytomas; PD: Increase of &gt;25% from lowest response value in any one of following: Serum M-component (absolute increase must be &gt;0.5 g/dL)4 and/or Urine M-component (absolute increase must be &gt;200 mg/24 h) and/or &gt;10 mg/dL absolute increase in difference between involved and uninvolved FLC levels, &gt;=10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) attributed solely to plasma cell proliferative disorder.</description>
          <population>Analysis was performed only on subset of population who had response in Phase 2 stage 2.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="5.2"/>
                    <measurement group_id="O2" value="10.9" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Percentage of Participants With Clinical Benefit</title>
        <description>Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum &amp; urine, disappearance of any soft tissue plasmacytomas,&lt;5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum &amp; urine M-component detectable by immunofixation, not on electrophoresis/,&gt;=90% reduction in serum M-component plus urine M-component level &lt;100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:&gt;=25 but &lt;49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas.</description>
        <time_frame>From Baseline up to 30 days after the last dose (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed on AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Percentage of Participants With Clinical Benefit</title>
          <description>Clinical benefit: participants with sCR, CR, VGPR, PR or MR as per IMWG criteria, determined by IAC. CR: negative immunofixation on serum &amp; urine, disappearance of any soft tissue plasmacytomas,&lt;5% PCs in bone marrow aspirates. sCR: CR + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum &amp; urine M-component detectable by immunofixation, not on electrophoresis/,&gt;=90% reduction in serum M-component plus urine M-component level &lt;100mg/24hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to &lt;200 mg/24 hours, ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline, ≥50% size reduction in soft tissue plasmacytomas. MR:&gt;=25 but &lt;49% reduction in serum M-protein, reduction in 24h urine M-protein by 50-89%, 25-49% size reduction in soft tissue plasmacytomas.</description>
          <population>Analysis was performed on AT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="41.7"/>
                    <measurement group_id="O3" value="32.0"/>
                    <measurement group_id="O4" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 2: Percentage of Participants With Clinical Benefit</title>
        <description>Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum &amp; urine, disappearance of any soft tissue plasmacytomas,&lt;5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum &amp; urine M-component detectable by immunofixation, not on electrophoresis/,&gt;=90% reduction in serum M-component plus urine M-component level &lt;100mg/24h/,&gt;=90% decrease in difference between involved and uninvolved FLC levels; PR:&gt;=50% reduction of serum M-protein, reduction in 24h urinary M-protein by &gt;=90%/&lt;200mg/24h,&gt;50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, &gt;=50% reduction in size/number of soft tissue plasmacytomas. MR:&gt;=25 but &lt;49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas</description>
        <time_frame>From the date of randomization to the date of first documentation of progression or death (maximum duration: 97 weeks )</time_frame>
        <population>Analysis was performed on AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 2: Percentage of Participants With Clinical Benefit</title>
          <description>Clinical benefit:participants with sCR, CR, VGPR, PR or MR, per IMWG criteria, determined by IAC. CR:negative immunofixation on serum &amp; urine, disappearance of any soft tissue plasmacytomas,&lt;5% plasma cells in bone marrow aspirates,normal FLC ratio(0.26-1.65) in participants with only FLC disease.sCR:CR+normal FLC ratio, absence of clonal cells in bone marrow biopsy.VGPR:serum &amp; urine M-component detectable by immunofixation, not on electrophoresis/,&gt;=90% reduction in serum M-component plus urine M-component level &lt;100mg/24h/,&gt;=90% decrease in difference between involved and uninvolved FLC levels; PR:&gt;=50% reduction of serum M-protein, reduction in 24h urinary M-protein by &gt;=90%/&lt;200mg/24h,&gt;50% decrease in difference between involved and uninvolved FLC in place of M-protein criteria, &gt;=50% reduction in size/number of soft tissue plasmacytomas. MR:&gt;=25 but &lt;49% reduction in serum M-protein,reduction in 24h urine M-protein by 50-89%, 25-49% reduction in size of soft tissue plasmacytomas</description>
          <population>Analysis was performed on AT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1"/>
                    <measurement group_id="O2" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of &gt; 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL), Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h), &gt; 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, &gt;10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed on AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression (PD) or date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of &gt; 25% from lowest response value in any one or more of the following: Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL), Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h), &gt; 10mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, &gt;10% absolute percentage of bone marrow plasma cell, definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas, development of hypercalcemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.</description>
          <population>Analysis was performed on AT population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.02" upper_limit="5.49"/>
                    <measurement group_id="O2" value="9.6" lower_limit="2.23" upper_limit="NA">Upper limit of confidence interval was not estimable due to less number of participants with event.</measurement>
                    <measurement group_id="O3" value="4.4" lower_limit="1.84" upper_limit="5.82"/>
                    <measurement group_id="O4" value="3.6" lower_limit="1.91" upper_limit="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 2: Progression Free Survival</title>
        <description>PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of &gt;25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be &gt;0.5 g/dL)4 and/or Urine M-component (the absolute increase must be &gt;200 mg/24 h) and/or &gt;10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>From the date of the first dose administration until progression or death, whichever occurred first (maximum duration: 97 weeks)</time_frame>
        <population>Analysis was performed on AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 2: Progression Free Survival</title>
          <description>PFS was defined as the time interval from the date of first isatuximab administration to the date of the first IAC-confirmed disease progression or the date of death due to any cause, whichever came first. As per IMWG criteria, PD: Increase of &gt;25% from lowest response value in any one of the following: Serum M-component (the absolute increase must be &gt;0.5 g/dL)4 and/or Urine M-component (the absolute increase must be &gt;200 mg/24 h) and/or &gt;10 mg/dL decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria, ≥10% bone marrow plasma cell, development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL) attributed solely to the plasma cell proliferative disorder. Analysis was performed by Kaplan-Meier method.</description>
          <population>Analysis was performed on AT population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" lower_limit="3.877" upper_limit="7.688"/>
                    <measurement group_id="O2" value="10.15" lower_limit="4.862" upper_limit="17.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Overall Survival (OS)</title>
        <description>OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>From the date of randomization to date of death from any cause (maximum duration 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed on AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Overall Survival (OS)</title>
          <description>OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.</description>
          <population>Analysis was performed on AT population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.277" lower_limit="4.7310" upper_limit="NA">Upper limit of Confidence Interval (CI) was not estimable, due to less number of participants with event.</measurement>
                    <measurement group_id="O2" value="18.628" lower_limit="7.7536" upper_limit="20.1068"/>
                    <measurement group_id="O3" value="NA" lower_limit="8.4435" upper_limit="NA">Median and upper limit of CI was not estimable, due to less number of participants with event.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="8.3450" upper_limit="NA">Median and upper limit of CI was not estimable, due to less number of participants with event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 2: Overall Survival</title>
        <description>OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>From the date of randomization to date of death from any cause (maximum duration: 97 weeks)</time_frame>
        <population>Analysis was performed on AT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 2: Overall Survival</title>
          <description>OS was defined as the time interval from the date of first Isatuximab administration to death from any cause. Analysis was performed by Kaplan-Meier method.</description>
          <population>Analysis was performed on AT population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92" lower_limit="13.602" upper_limit="23.064"/>
                    <measurement group_id="O2" value="17.25" lower_limit="15.409" upper_limit="NA">Upper limit of CI was not estimable, due to less number of participants with event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores: Global Health Status</title>
        <description>EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) &amp; other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health &amp; quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 &amp; 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.</description>
        <time_frame>Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and End of Treatment (EOT: anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed on AT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure and 'number analyzed' = number of participants with available data for each category.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Scores: Global Health Status</title>
          <description>EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) &amp; other single items. For each item, high score = high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health &amp; quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 &amp; 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.</description>
          <population>Analysis was performed on AT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure and 'number analyzed' = number of participants with available data for each category.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="20.15"/>
                    <measurement group_id="O2" value="2.22" spread="16.51"/>
                    <measurement group_id="O3" value="-3.95" spread="20.67"/>
                    <measurement group_id="O4" value="0.00" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="19.25"/>
                    <measurement group_id="O2" value="-0.76" spread="16.44"/>
                    <measurement group_id="O3" value="6.55" spread="19.66"/>
                    <measurement group_id="O4" value="-2.08" spread="15.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="24.53"/>
                    <measurement group_id="O2" value="-5.30" spread="21.50"/>
                    <measurement group_id="O3" value="6.06" spread="21.11"/>
                    <measurement group_id="O4" value="7.41" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="24.53"/>
                    <measurement group_id="O2" value="0.69" spread="15.27"/>
                    <measurement group_id="O3" value="6.48" spread="21.15"/>
                    <measurement group_id="O4" value="5.00" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="14.43"/>
                    <measurement group_id="O2" value="-10.19" spread="25.27"/>
                    <measurement group_id="O3" value="5.95" spread="13.36"/>
                    <measurement group_id="O4" value="10.42" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="5.89"/>
                    <measurement group_id="O2" value="-3.57" spread="15.85"/>
                    <measurement group_id="O3" value="8.33" spread="11.79"/>
                    <measurement group_id="O4" value="6.67" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="35.36"/>
                    <measurement group_id="O2" value="-11.11" spread="18.76"/>
                    <measurement group_id="O3" value="4.17" spread="15.96"/>
                    <measurement group_id="O4" value="6.25" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="11.79"/>
                    <measurement group_id="O2" value="-10.00" spread="19.90"/>
                    <measurement group_id="O3" value="4.17" spread="14.43"/>
                    <measurement group_id="O4" value="6.25" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.33" spread="35.36"/>
                    <measurement group_id="O2" value="-16.67" spread="22.05"/>
                    <measurement group_id="O3" value="8.33" spread="11.79"/>
                    <measurement group_id="O4" value="3.33" spread="7.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="33.64"/>
                    <measurement group_id="O2" value="-11.67" spread="13.94"/>
                    <measurement group_id="O3" value="-11.11" spread="20.97"/>
                    <measurement group_id="O4" value="-12.50" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20) Scores: Disease Symptom Subscale Score</title>
        <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL.</description>
        <time_frame>Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10 and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed on AT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure and 'number analyzed' = number of participants with available data for each category.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Specific Module With 20 Items (EORTC QLQ-MY20) Scores: Disease Symptom Subscale Score</title>
          <description>EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with MM. It has 4 subscales: body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). Disease symptoms subscale used 4-point scale ranged from 1= 'Not at All' to 4= 'Very Much'. Scores were averaged, and transformed to 0 -100 scale, where higher scores = more symptoms and lower health-related quality of life (HRQL) and lower score = less symptoms and more HRQL.</description>
          <population>Analysis was performed on AT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure and 'number analyzed' = number of participants with available data for each category.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="18.36"/>
                    <measurement group_id="O2" value="-3.42" spread="11.24"/>
                    <measurement group_id="O3" value="0.93" spread="13.91"/>
                    <measurement group_id="O4" value="2.61" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" spread="11.94"/>
                    <measurement group_id="O2" value="-5.05" spread="14.15"/>
                    <measurement group_id="O3" value="-5.98" spread="16.89"/>
                    <measurement group_id="O4" value="-1.52" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" spread="13.22"/>
                    <measurement group_id="O2" value="-3.89" spread="16.98"/>
                    <measurement group_id="O3" value="-10.00" spread="16.93"/>
                    <measurement group_id="O4" value="0.62" spread="30.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.94" spread="10.52"/>
                    <measurement group_id="O2" value="0.51" spread="19.95"/>
                    <measurement group_id="O3" value="-9.03" spread="17.04"/>
                    <measurement group_id="O4" value="-6.67" spread="17.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" spread="7.17"/>
                    <measurement group_id="O2" value="1.23" spread="23.53"/>
                    <measurement group_id="O3" value="-15.08" spread="20.96"/>
                    <measurement group_id="O4" value="-6.94" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" spread="3.93"/>
                    <measurement group_id="O2" value="-3.70" spread="22.95"/>
                    <measurement group_id="O3" value="-18.06" spread="21.93"/>
                    <measurement group_id="O4" value="-11.11" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" spread="7.86"/>
                    <measurement group_id="O2" value="-2.78" spread="23.50"/>
                    <measurement group_id="O3" value="-15.28" spread="23.30"/>
                    <measurement group_id="O4" value="-4.17" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="7.86"/>
                    <measurement group_id="O2" value="-10.00" spread="10.69"/>
                    <measurement group_id="O3" value="-16.67" spread="29.75"/>
                    <measurement group_id="O4" value="-6.94" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="19.25"/>
                    <measurement group_id="O3" value="-15.28" spread="30.56"/>
                    <measurement group_id="O4" value="-6.67" spread="17.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.72" spread="19.44"/>
                    <measurement group_id="O2" value="7.78" spread="24.41"/>
                    <measurement group_id="O3" value="24.07" spread="22.45"/>
                    <measurement group_id="O4" value="25.00" spread="35.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 2 Stage 1: Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D) Generic Health Status - Visual Analogue Scale Scores</title>
        <description>EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.</description>
        <time_frame>Baseline, Day 1 of Cycles 4, 7, 10, 13, 16, 19, and EOT (anytime up to 77 weeks for Stage 1a arms and 53 weeks for stage 1b arm)</time_frame>
        <population>Analysis was performed on AT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure and 'number analyzed' = number of participants with available data for each category.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
            <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Q4W, i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
            <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 Stage 1: Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D) Generic Health Status - Visual Analogue Scale Scores</title>
          <description>EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.</description>
          <population>Analysis was performed on AT population. Here, &quot;Overall Number of Participants Analyzed&quot; = participants evaluable for this outcome measure and 'number analyzed' = number of participants with available data for each category.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 4 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.75" spread="18.55"/>
                    <measurement group_id="O2" value="2.00" spread="16.88"/>
                    <measurement group_id="O3" value="-4.78" spread="15.71"/>
                    <measurement group_id="O4" value="4.89" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="0.71"/>
                    <measurement group_id="O2" value="-6.00" spread="27.39"/>
                    <measurement group_id="O3" value="9.00" spread="18.25"/>
                    <measurement group_id="O4" value="1.00" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="2.12"/>
                    <measurement group_id="O2" value="-10.33" spread="9.29"/>
                    <measurement group_id="O3" value="10.33" spread="24.38"/>
                    <measurement group_id="O4" value="-2.60" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="19.80"/>
                    <measurement group_id="O2" value="-5.00" spread="4.00"/>
                    <measurement group_id="O3" value="-9.00"/>
                    <measurement group_id="O4" value="-5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="5.66"/>
                    <measurement group_id="O2" value="0.67" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-5.50" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.50" spread="16.98"/>
                    <measurement group_id="O2" value="-11.60" spread="11.37"/>
                    <measurement group_id="O3" value="-10.00" spread="9.54"/>
                    <measurement group_id="O4" value="-9.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval</title>
        <time_frame>Pre-dose, at the end of infusion, 1 hour and 168 hours post dose on Day 1 of Cycle 1</time_frame>
        <population>Analysis was performed on PK population which included participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 1 Week Interval</title>
          <population>Analysis was performed on PK population which included participants who gave informed consent, received at least one dose (even if incomplete) of isatuximab, had an assessable PK parameter.</population>
          <units>mcg*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37096" spread="80"/>
                    <measurement group_id="O2" value="35423" spread="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval</title>
        <time_frame>Cycle 1, Day 1: pre-dose, at the end of infusion, 168 and 336 hours post-infusion</time_frame>
        <population>Analysis was performed on PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 2 Weeks Interval</title>
          <population>Analysis was performed on PK population.</population>
          <units>mcg*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91271" spread="78"/>
                    <measurement group_id="O2" value="86761" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval</title>
        <time_frame>Cycle 1, Day 1: pre-dose, at the end of infusion, 168, 336, and 672 hours post-infusion</time_frame>
        <population>Analysis was performed on PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Area Under the Plasma Concentration Versus Time Curve of Isatuximab Over 4 Weeks Interval</title>
          <population>Analysis was performed on PK population.</population>
          <units>mcg*hour/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236360" spread="72"/>
                    <measurement group_id="O2" value="226372" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Plasma Concentration of Isatuximab Before Treatment Administration (Ctrough)</title>
        <time_frame>At Day 1, 8, and 22</time_frame>
        <population>Analysis was performed on PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Plasma Concentration of Isatuximab Before Treatment Administration (Ctrough)</title>
          <population>Analysis was performed on PK population.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" spread="75"/>
                    <measurement group_id="O2" value="128" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230" spread="70"/>
                    <measurement group_id="O2" value="214" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" spread="63"/>
                    <measurement group_id="O2" value="305" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Accumulation Ratio of Isatuximab Based on Ctrough</title>
        <description>Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8.</description>
        <time_frame>Cycle 2, Day 1; Cycle 1, Day 8; Cycle 4, Day 1</time_frame>
        <population>Analysis was performed on PK population. Here, ‘number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Assessment: Phase 2 Stage 2: Accumulation Ratio of Isatuximab Based on Ctrough</title>
          <description>Ctrough is the plasma concentration observed before treatment administration. For 1st category, the accumulation ratio was calculated by dividing Ctrough value of Cycle 2 Day 1 by Cycle 1 Day 8 and for second category, accumulation ratio was calculated by dividing Ctrough value of Cycle 4 Day 1 by Cycle 1 Day 8.</description>
          <population>Analysis was performed on PK population. Here, ‘number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2 Day 1/Cycle 1 Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="521.38338" spread="4891.63390"/>
                    <measurement group_id="O2" value="3.24370" spread="1.73860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1/Cycle 1 Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58378" spread="2.77398"/>
                    <measurement group_id="O2" value="3.95950" spread="3.19310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Assessment: Phase 2 Stage 2: Number of Participants With Anti-drug Antibodies to Isatuximab</title>
        <description>ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.</description>
        <time_frame>Up to 97 weeks</time_frame>
        <population>Analysis was performed on ADA evaluable population which included all treated participants with at least one ADA assessment with a reportable result during the ADA on-study observation period.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2 Stage 2: Isatuximab Alone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
          <group group_id="O2">
            <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
            <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion(40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Assessment: Phase 2 Stage 2: Number of Participants With Anti-drug Antibodies to Isatuximab</title>
          <description>ADA response was categorized as: treatment induced and treatment boosted response. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period (defined as the time from the first isatuximab administration until end of Phase 2 Stage 2) in participants without preexisting ADA (defined as: ADA that were present in samples drawn before treatment), including participants without pre-treatment (before treatment) samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment (before treatment) and post-treatment.</description>
          <population>Analysis was performed on ADA evaluable population which included all treated participants with at least one ADA assessment with a reportable result during the ADA on-study observation period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment induced ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment boosted ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs were collected from signing of the informed consent form up to last administration of study treatment (up to 120 weeks for Phase 1, 77 weeks for Phase 2 Stage 1a, 53 weeks for Phase 2 Stage 1b, and 97 weeks for Phase 2 Stage 2) regardless of seriousness or relationship to investigational product.</time_frame>
      <desc>Reported AEs and deaths were TEAEs which was defined as an AE that developed or worsened during the ‘on treatment period’ (time from the first dose of any study treatment up to 30 days after the last administration of the study treatment). Analysis was performed on AT population. For Phase 1 and Phase 2 Stage 1, MedDRA 19.1 version was used and for Phase 2 Stage 2, MedDRA 22.0 version was used.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1: Isatuximab 1mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 1 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E2">
          <title>Phase 1: Isatuximab 3mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E3">
          <title>Phase 1: Isatuximab 5mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E4">
          <title>Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)</title>
          <description>Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this in arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E5">
          <title>Phase 1: Isatuximab (CD38 + HM and High Risk Multiple Myeloma)</title>
          <description>Participants with CD38+ HM along with participants with high risk multiple myeloma were included this in arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E6">
          <title>Phase 1: Isatuximab 10mg/kg QW</title>
          <description>Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E7">
          <title>Phase 1: Isatuximab 20mg/kg Q2W</title>
          <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E8">
          <title>Phase 1: Isatuximab 20mg/kg QW</title>
          <description>Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of DLT, disease progression, death, consent withdrawal, investigator’s decision, and/or availability of study drug (maximum exposure: 120 weeks).</description>
        </group>
        <group group_id="E9">
          <title>Phase 2 Stage 1a: Isatuximab 3mg/kg Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="E10">
          <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="E11">
          <title>Phase 2 Stage 1a: Isatuximab 10mg/kg Q2W; Then Q4W</title>
          <description>Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).</description>
        </group>
        <group group_id="E12">
          <title>Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W</title>
          <description>Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then Day 1 of each 28-days cycle until Unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).</description>
        </group>
        <group group_id="E13">
          <title>Phase 2 Stage 2: Isatuximab Alone</title>
          <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
        </group>
        <group group_id="E14">
          <title>Phase 2 Stage 2: Isatuximab + Dexamethasone</title>
          <description>Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion tablet or as IV infusion (40 mg/day for &lt;75 years of age; 20 mg/day for &gt;=75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator’s decision (maximum exposure: 97 weeks).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1 and 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="51" subjects_at_risk="109"/>
                <counts group_id="E14" subjects_affected="25" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperviscosity Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Stress Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia Of Malignancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diverticular Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Mechanical Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Obstruction Gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Feeling Cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Impaired Self-Care</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Performance Status Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Campylobacter Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Haemophilus Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Infectious Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Infective Aortitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Meningitis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Meningococcal Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Parainfluenzae Virus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumococcal Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumocystis Jirovecii Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia Mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia Respiratory Syncytial Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia Streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pulmonary Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Varicella Zoster Virus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Traumatic Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tumour Lysis Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Plasma Cell Leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma Of The Oral Cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnoea At Rest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Laryngeal Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngeal Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory Alkalosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Extrinsic Iliac Vein Compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1 and 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="23"/>
                <counts group_id="E10" subjects_affected="23" subjects_at_risk="24"/>
                <counts group_id="E11" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E12" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E13" subjects_affected="91" subjects_at_risk="109"/>
                <counts group_id="E14" subjects_affected="47" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="14" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="10" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E12" events="12" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="9" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Right Ventricular Hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Scleral Discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="7" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominal Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="12" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E9" events="7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E10" events="13" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E11" events="11" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E12" events="9" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E13" events="31" subjects_affected="21" subjects_at_risk="109"/>
                <counts group_id="E14" events="16" subjects_affected="10" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="6" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E10" events="14" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E11" events="16" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E12" events="8" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E13" events="18" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E14" events="32" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E11" events="9" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E12" events="10" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E13" events="15" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="9" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E14" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E11" events="12" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="10" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E14" events="5" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E10" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E11" events="12" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E12" events="9" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E13" events="30" subjects_affected="18" subjects_at_risk="109"/>
                <counts group_id="E14" events="12" subjects_affected="10" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Implant Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="6" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine Release Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Angular Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E14" events="4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="5" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="7" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="8" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E10" events="15" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E11" events="16" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E12" events="8" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E13" events="16" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E14" events="8" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="8" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E5" events="13" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E8" events="74" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E9" events="11" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E10" events="17" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E11" events="14" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E12" events="16" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E13" events="41" subjects_affected="38" subjects_at_risk="109"/>
                <counts group_id="E14" events="21" subjects_affected="20" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Scapula Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sports Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Carbon Monoxide Diffusing Capacity Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T Wave Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="9" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Qrs Axis Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E13" events="11" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pseudohyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="11" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E14" events="9" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="5" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="8" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="24" subjects_affected="21" subjects_at_risk="109"/>
                <counts group_id="E14" events="10" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="12" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Limb Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Muscle Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="9" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" events="8" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="9" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" events="8" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E14" events="10" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Spinal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tumour Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cognitive Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cranial Nerve Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="5" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Head Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="33" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E11" events="8" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E12" events="8" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E13" events="19" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E14" events="8" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Mental Impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Restless Legs Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Toxic Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vith Nerve Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="4" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="16" subjects_affected="14" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nipple Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E10" events="11" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E11" events="10" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E12" events="11" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E13" events="22" subjects_affected="19" subjects_at_risk="109"/>
                <counts group_id="E14" events="13" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E11" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" events="19" subjects_affected="17" subjects_at_risk="109"/>
                <counts group_id="E14" events="7" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Laryngeal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="10" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Throat Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Throat Tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Tracheal Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper-Airway Cough Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic Keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dermatitis Acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hair Texture Abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain Of Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash Erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash Macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash Maculo-Papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skin Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="39" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E12" events="5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Peripheral Coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

